Acute Idiopathic Maculopathy Following SARS-CoV-2 Vaccination

Ocul Immunol Inflamm. 2023 Aug;31(6):1232-1235. doi: 10.1080/09273948.2022.2114915. Epub 2022 Sep 2.

Abstract

A 49-year-old man presented with acute unilateral blurred vision one week after SARS-CoV-2 vaccination. A unilateral serous detachment of the macula, intraretinal hemorrhages, vitritis, and anterior chamber cell was found. Diagnostic testing was negative for infectious and inflammatory causes, and a diagnosis of acute idiopathic maculopathy (AIM) was made. Symptoms and serous detachment resolved over 12 weeks, with residual retinal pigment epithelial changes consistent with the disease course. AIM is a rare diagnosis that presented in close proximity to SARS-CoV-2 vaccination without evidence of coxsackievirus infection. Further research is necessary to clarify an association between this vaccine and uveitis.

Keywords: COVID; SARS-CoV-2; maculopathy; uveitis; vaccine.

Publication types

  • Case Reports

MeSH terms

  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / complications
  • Fluorescein Angiography
  • Humans
  • Macular Degeneration*
  • Male
  • Middle Aged
  • Retinal Diseases* / diagnosis
  • SARS-CoV-2
  • Vaccination / adverse effects

Substances

  • COVID-19 Vaccines